Navigation Links
China Shenghuo Receives Notice from NYSE Alternext US Regarding Listing Standards
Date:2/17/2009

KUNMING, China, Feb. 17 /PRNewswire-Asia-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China Shenghuo" or the "Company"), today announced that on February 10, 2009, it received a deficiency letter from the NYSE Alternext US LLC ("NYSE Alternext US" or the "Exchange") stating that the Company was not in compliance with Section 704 of the Exchange's continued listing standards due to the Company's failure to hold an annual meeting of stockholders in 2008. The Company was given an opportunity to submit a plan of compliance (a "Plan") to the Exchange by March 10, 2009 to demonstrate the Company's ability to regain compliance with Section 704 by August 11, 2009.

Because the Company restated certain of its financial statements during November 2008, the Company was unable to deliver its annual report and proxy statement to its stockholders during 2008. As such, the Company failed to hold an annual meeting of stockholders during 2008.

The Company anticipates holding its annual meeting of stockholders on or about May 20, 2009 and will submit its Plan to advise the Exchange of this prior to March 10, 2009. The Company believes that so holding the annual meeting will cure the deficiency, and the Company intends to hold future annual meetings of stockholders on an annual basis, in accordance with the Exchange's listing standards.

If the Company does not submit a Plan by March 10, 2009, the Exchange rejects the Plan, or the Company does not implement an accepted Plan by August 11, 2009, the Company will be subject to delisting proceedings.

About China Shenghuo

Founded in 1995, China Shenghuo is a specialty pharmaceutical company that focuses on the research, development, manufacture and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn .

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, risks of litigation and governmental or other regulatory proceedings arising out of or related to any of the matters described in recent press releases, including arising out of the restatement of the Company's financial statements; the Company's continuing ability to satisfy any requirements which may be prescribed by the Exchange for continued listing on the Exchange; risks arising from potential weaknesses or deficiencies in the Company's internal controls over financial reporting; the Company's reliance on one supplier for Sanchi; the possible effect of adverse publicity on the Company's business, including possible contract cancellation; the Company's ability to develop and market new products; the Company's ability to establish and maintain a strong brand; the Company's continued ability to obtain and maintain all certificates, permits and licenses required to open and operate retail specialty counters to offer its cosmetic products and conduct business in China; protection of the Company's intellectual property rights; market acceptance of the Company's products; changes in the laws of the People's Republic of China that affect the Company's operations; cost to the Company of complying with current and future governmental regulations; the impact of any changes in governmental regulations on the Company's operations; general economic conditions; and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

    China Shenghuo Pharmaceutical Holdings, Inc.
     Mr. Changhua Mu
     Securities Affairs Representative
     Tel:   +86-871-7282-698
     Email: c.mu@chinashenghuo.net

    Grayling
     Eddie Cheung
     Investor Relations
     Tel:   +1-646-284-9414
     Email: echeung@hfgcg.com

'/>"/>
SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. China-Biotics, Inc. Reports Third Quarter 2009 Financial Results
2. Senator James Sasser, Former Ambassador to China, Joins Neuralstem Advisory Board
3. China-Biotics, Inc. Announces Conference Call to Discuss Third Quarter 2009 Financial Results
4. China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update
5. China Medical Technologies to Announce Financial Results for the Third Fiscal Quarter Ended December 31, 2008 on March 2, 2009
6. Shengtai Pharmaceutical, Inc. Comments on Chinas Recently Approved Health Care Reform Plan
7. Tainted China Formula Caused High Rate of Kidney Stones in Kids
8. AMDL, Inc. Chairman & CEO Announces Expert Opinion on Chinas Economic Forecast
9. China Medical Technologies Announces the Receipt of SFDA Approval for Two of its FISH Probes and the Approval for the Hi-Tech Enterprise Status for its PRC Subsidiaries
10. China Pharma Holdings, Inc., Financial Year 2008 Preview
11. Immtech Announces Sale of Property Subsidiary in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: